Lipoic acid prevents the changes of intracellular lipid partitioning by free fatty acid

Gut and Liver

Volumn 7, Issue 2, 2013, Pages 221-227

  Kim, Dong Chan ^a   Jun, Dae Won ^a   Jang, Eun Chul ^b   Kim, Sang Heum ^a   Kim, Eun Kyung ^c   Lee, Sang Pyo ^a   Lee, Kang Nyeong ^a   Lee, Hang Lak ^a   Lee, Oh Young ^a   Yoon, Byung Chul ^a   Choi, Ho Soon ^a  

^a Hanyang University College of Medicine   (South Korea)

^b Soonchunhyang University College of Medicine   (South Korea)

^c Eulji University School of Medicine   (South Korea)

Author keywords

Lipid partitioning; Lipotoxicity; Liver cirrhosis; Non Alcoholic steatohepatitis; Thioctic acid

Indexed keywords

CHOLESTEROL; FATTY ACID; PALMITIC ACID; REACTIVE OXYGEN METABOLITE; THIOCTIC ACID;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL MEMBRANE; CONTROLLED STUDY; CYTOPLASM; GENE DOSAGE; HUMAN; HUMAN CELL; LIPID COMPOSITION; LIPID LIVER LEVEL; LIPOTOXICITY; LIVER CELL; MORPHOLOGY; NONALCOHOLIC FATTY LIVER;

EID: 84875119816     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl.2013.7.2.221     Document Type: Article

References (38)

1. Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012;142:711-725.
2. Cusi K. Role of insulin resistance and lipotoxicity in non-Alcoholic steatohepatitis. Clin Liver Dis 2009;13:545-563.
3. Fujii H, Kawada N. Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol 2012;47:215-225.
4. Mollica MP, Lionetti L, Putti R, Cavaliere G, Gaita M, Barletta A. From chronic overfeeding to hepatic injury: role of endoplasmic reticulum stress and inflammation. Nutr Metab Cardiovasc Dis 2011;21:222-230.
5. Choudhury J, Sanyal AJ. Insulin resistance in NASH. Front Biosci 2005;10:1520-1533.
6. Haque M, Sanyal AJ. The metabolic abnormalities associated with non-Alcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 2002;16:709-731.
7. Park JH. Insulin resistance in non-Alcoholic fatty liver disease. Korean J Hepatol 2006;12:16-30.
8. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. Hepatology 2005;42:987-1000.
9. Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 2009;9:299-314.
10. Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007;45:1366-1374.
11. Amaro A, Fabbrini E, Kars M, et al. Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology 2010;139:149-153.
12. Li ZZ, Berk M, McIntyre TM, Feldstein AE. Hepatic lipid partitioning and liver damage in nonalcoholic fatty liver disease: role of stearoyl-CoA desaturase. J Biol Chem 2009;284:5637-5644.
13. Landry F, Chan CC, Huang Z, et al. Plasma-based approach to measure target engagement for liver-targeting stearoyl-CoA desaturase 1 inhibitors. J Lipid Res 2011;52:1494-1499.
14. Pan ZX, Han CC, Wang JW, et al. Cloning and expression of stearoyl-CoA desaturase 1 (SCD-1) in the liver of the Sichuan white goose and landes goose responding to overfeeding. Mol Biol Rep 2011;38:3417-3425.
15. Mari M, Caballero F, Colell A, et al. Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis. Cell Metab 2006;4:185-198.
16. Biewenga GP, Haenen GR, Bast A. The pharmacology of the antioxidant lipoic acid. Gen Pharmacol 1997;29:315-331.
17. Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Radic Biol Med 1995;19:227-250.
18. Mattulat A, Baltes W. Determination of lipoic acid in meat of commercial quality. Z Lebensm Unters Forsch 1992;194:326-329.
19. Kataoka H, Hirabayashi N, Makita M. Analysis of lipoic acid by gas chromatography with flame photometric detection. Methods Enzymol 1997;279:166-176.
20. Salinthone S, Yadav V, Bourdette DN, Carr DW. Lipoic acid: a novel therapeutic approach for multiple sclerosis and other chronic inflammatory diseases of the CNS. Endocr Metab Immune Disord Drug Targets 2008;8:132-142.
21. Simbula G, Columbano A, Ledda-Columbano GM, et al. Increased ROS generation and p53 activation in alpha-lipoic acid-induced apoptosis of hepatoma cells. Apoptosis 2007;12:113-123.
22. Mijnhout GS, Kollen BJ, Alkhalaf A, Kleefstra N, Bilo HJ. Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-Analysis of randomized controlled trials. Int J Endocrinol 2012;2012:456279.
23. Papanas N, Maltezos E. alpha-Lipoic acid, diabetic neuropathy, and Nathan's prophecy. Angiology 2012;63:81-83.
24. McIlduff CE, Rutkove SB. Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy. Ther Clin Risk Manag 2011;7:377-385.
25. Gu XM, Zhang SS, Wu JC, et al. Efficacy and safety of high-dose alpha-lipoic acid in the treatment of diabetic polyneuropathy. Zhonghua Yi Xue Za Zhi 2010;90:2473-2476.
26. Mijnhout GS, Alkhalaf A, Kleefstra N, Bilo HJ. Alpha lipoic acid: a new treatment for neuropathic pain in patients with diabetes? Neth J Med 2010;68:158-162.
27. Xiang G, Pu J, Yue L, Hou J, Sun H. alpha-lipoic acid can improve endothelial dysfunction in subjects with impaired fasting glucose. Metabolism 2011;60:480-485.
28. Heinisch BB, Francesconi M, Mittermayer F, et al. Alpha-lipoic acid improves vascular endothelial function in patients with type 2 diabetes: a placebo-controlled randomized trial. Eur J Clin Invest 2010;40:148-154.
29. Tardif JC, Rhéaume E. Lipoic acid supplementation and endothelial function. Br J Pharmacol 2008;153:1587-1588.
30. Min AK, Kim MK, Kim HS, et al. Alpha-lipoic acid attenuates methionine choline deficient diet-induced steatohepatitis in C57BL/6 mice. Life Sci 2012;90:200-205.
31. Serviddio G, Bellanti F, Vendemiale G, Altomare E. Mitochondrial dysfunction in nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol 2011;5:233-244.
32. Jun DW, Cho WK, Jun JH, et al. Prevention of free fatty acid-induced hepatic lipotoxicity by carnitine via reversal of mitochondrial dysfunction. Liver Int 2011;31:1315-1324.
33. Lim CY, Jun DW, Jang SS, Cho WK, Chae JD, Jun JH. Effects of carnitine on peripheral blood mitochondrial DNA copy number and liver function in non-Alcoholic fatty liver disease. Korean J Gastroenterol 2010;55:384-389.
34. Maczurek A, Hager K, Kenklies M, et al. Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease. Adv Drug Deliv Rev 2008;60:1463-1470.
35. Valdecantos MP, Pérez-Matute P, González-Muniesa P, Prieto-Hontoria PL, Moreno-Aliaga MJ, Martínez JA. Lipoic acid improves mitochondrial function in nonalcoholic steatosis through the stimulation of sirtuin 1 and sirtuin 3. Obesity (Silver Spring) 2012;20:1974-1983.
36. Celik S, Ozkaya A. Effects of intraperitoneally administered lipoic acid, vitamin E, and linalool on the level of total lipid and fatty acids in guinea pig brain with oxidative stress induced by H2O2. J Biochem Mol Biol 2002;35:547-552.
37. Yilmaz O, Ozkan Y, Yildirim M, Oztürk AI, Er?an Y. Effects of alpha lipoic acid, ascorbic acid-6-palmitate, and fish oil on the glutathione, malonaldehyde, and fatty acids levels in erythrocytes of streptozotocin induced diabetic male rats. J Cell Biochem 2002;86:530-539.
38. Fernández A, Llacuna L, Fernández-Checa JC, Colell A. Mitochondrial cholesterol loading exacerbates amyloid beta peptide-induced inflammation and neurotoxicity. J Neurosci 2009;29:6394-6405.